MINK THERAPEUTICS INC (INKT) Stock News
NASDAQ:INKT - Nasdaq - US6036931029 - Common Stock - Currency: USD
INKT Latest News, Press Releases and Analysis
Top movers analysis one hour before the close of the markets on 2025-01-28: top gainers and losers in today's session.
Curious about what's happening in today's session? Check out the latest stock movements and price changes.
These stocks are moving in today's session
Let's have a look at what is happening on the US markets in the middle of the day on Tuesday. Below you can find the top gainers and losers in today's session.
The market is filled with gapping stocks in Tuesday's session.
The market is buzzing with gapping stocks on Tuesday. Let's uncover which stocks are experiencing notable gaps during today's session.
MiNK Therapeutics Targets Immune Reconstitution to Combat Advanced Gastroesophageal Cancers with Novel Combination of Allo-iNKTs plus BOT/BAL at ASCO GI
NEW YORK, Jan. 23, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the development...
MiNK Therapeutics to Present iNKT Cell Therapy in Gastric Cancer at ASCO GI Annual Meeting
Presentation will feature the ongoing Phase 2 study of agenT-797 in refractory gastric cancer
MiNK Therapeutics to Present iNKT Cell Therapy in Gastric Cancer at ASCO GI Annual Meeting
Presentation will feature the ongoing Phase 2 study of agenT-797 in refractory gastric cancer...
MiNK Therapeutics Reports Third Quarter 2024 Results and Business Update
MiNK Therapeutics Reports Third Quarter 2024 Results and Business Update
NEW YORK, Nov. 14, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery,...
MiNK Therapeutics to Provide Corporate Update and Third Quarter 2024 Financial Report
MiNK Therapeutics to Provide Corporate Update and Third Quarter 2024 Financial Report
NEW YORK, Nov. 11, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery,...
MiNK’s iNKT Cell Therapy Shows Potential for Optimal Multi-Combination for Resistant Solid Cancers at SITC 2024
MiNK’s iNKT Cell Therapy Shows Potential for Optimal Multi-Combination for Resistant Solid Cancers at SITC 2024
AgenT-797 Combination with Checkpoint Inhibitors and Bispecific Engagers Expands Anti-Cancer Benefit PRAME-TCR iNKT Overcomes Challenges from Conventional...
MiNK Therapeutics Announces Appointment of Dr. Robert Kadlec to Board of Directors
MiNK Therapeutics Announces Appointment of Dr. Robert Kadlec to Board of Directors
NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics (MiNK, NASDAQ: INKT), a clinical-stage company pioneering the development of allogeneic...
MiNK Therapeutics and Autonomous Therapeutics Announce Collaboration to Develop Novel Therapies Targeting Metastatic Tumors
MiNK Therapeutics and Autonomous Therapeutics Announce Collaboration to Develop Novel Therapies Targeting Metastatic Tumors
NEW YORK, Oct. 08, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics (MiNK, NASDAQ: INKT) a clinical-stage company pioneering the development of allogeneic...
MiNK Therapeutics to Present Data From iNKT Cell Programs at SITC 2024
MiNK Therapeutics to Present Data From iNKT Cell Programs at SITC 2024
NEW YORK, Oct. 04, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery,...
MiNK Therapeutics to Participate in H.C. Wainwright Global Investment Conference
MiNK Therapeutics to Participate in H.C. Wainwright Global Investment Conference
NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery,...
INKT Stock Earnings: MiNK Therapeutics Beats EPS for Q2 2024
INKT stock results show that MiNK Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.
INKT Stock Earnings: MiNK Therapeutics Beats EPS for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips MiNK Therapeutics (NASDAQ:INKT) just reported results for the second quarter of...
MiNK Reports Second Quarter 2024 Results and Business Update
MiNK Reports Second Quarter 2024 Results and Business Update
Expanded Access to AgenT-797 in Severe ARDS Reinforces Clinical Efficacy; Data Highlighted at ATS 2024 Annual MeetingPhase 2 Study in 2L Gastric Cancer...
MiNK Therapeutics to Provide Corporate Update and Second Quarter 2024 Financial Report
MiNK Therapeutics to Provide Corporate Update and Second Quarter 2024 Financial Report
NEW YORK, Aug. 01, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery,...
MiNK Therapeutics Regains Compliance with Nasdaq Capital Market Requirement
MiNK Therapeutics Regains Compliance with Nasdaq Capital Market Requirement
NEW YORK, July 31, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery,...
MiNK Therapeutics Announces Virtual Annual Shareholders Meeting
MiNK Therapeutics Announces Virtual Annual Shareholders Meeting
NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery,...
MiNK Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual Meeting
MiNK Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual Meeting
NEW YORK, May 22, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery,...
INKT Stock Earnings: MiNK Therapeutics Beats EPS for Q1 2024
INKT stock results show that MiNK Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.
MiNK Reports First Quarter 2024 Results
MiNK Reports First Quarter 2024 Results
Completed $5.8 million private placement financing at 25% premium Upcoming presentation of agenT-797 in severe respiratory distress at the American...